{"id":153251,"date":"2014-08-27T00:00:00","date_gmt":"2014-08-27T00:00:00","guid":{"rendered":"https:\/\/v2.optiknow.ca\/les-actionnaires-dallergan-discuteront-de-loffre-dachat-hostile-de-valeant\/"},"modified":"2014-08-27T00:00:00","modified_gmt":"2014-08-27T00:00:00","slug":"les-actionnaires-dallergan-discuteront-de-loffre-dachat-hostile-de-valeant","status":"publish","type":"post","link":"https:\/\/v2.optiknow.ca\/fr\/2014\/08\/27\/les-actionnaires-dallergan-discuteront-de-loffre-dachat-hostile-de-valeant\/","title":{"rendered":"Les actionnaires d\u0092Allergan discuteront de l\u0092offre d\u0092achat hostile de Valeant"},"content":{"rendered":"<p>\u00a0<\/p>\n<p>Allergan tiendra une r\u00e9union extraordinaire des actionnaires le 18 d\u00e9cembre 2014, afin de discuter de l'offre d'achat hostile de Valeant et Pershing Square Capital Management.<\/p>\n<p class=\"Corps\">\u00a0<\/p>\n<p class=\"Corps\">Cette r\u00e9union \u00e9tait r\u00e9clam\u00e9e par certains actionnaires, dont Pershing Square, elle-m\u00eame d\u00e9tentrice de 9,7\u00a0% du capital d'Allergan. Les actionnaires se verront notamment demander s'ils souhaitent que les administrateurs oppos\u00e9s \u00e0 la fusion avec Valeant quittent leur poste.<\/p>\n<p class=\"Corps\">\u00a0<\/p>\n<p class=\"Corps\">Le Conseil d'administration continue de soutenir que cette offre sous-estime largement sa valeur r\u00e9elle. L'entreprise vient de d\u00e9clarer les plus fortes ventes trimestrielles de son histoire, et entend r\u00e9duire ses co\u00fbts d'environ 475\u00a0M$ en\u00a02015 par rapport \u00e0 son plan strat\u00e9gique pr\u00e9c\u00e9dent. Elle pr\u00e9voit une croissance annuelle compos\u00e9e du b\u00e9n\u00e9fice par action de plus 20\u00a0% au cours des cinq prochaines ann\u00e9es.<\/p>\n<p class=\"Corps\">\u00a0<\/p>\n<p class=\"Corps\">Afin de contrer l'influence de Pershing Square dans ses propres rangs, Allergan a d\u00e9pos\u00e9 contre elle une poursuite en regard de la Loi f\u00e9d\u00e9rale sur les valeurs mobili\u00e8res, concernant l'achat des titres d'Allergan. Celui-ci est survenu quelques semaines \u00e0 peine avant que cette entreprise ne s'associe \u00e0 l'offre d'achat hostile de Valeant. Si la demande d'injonction d'Allergan, d\u00e9pos\u00e9e en Californie, est accept\u00e9e, Pershing Square ne pourra pas voter lors de la r\u00e9union extraordinaire.\u00a0<\/p>\n<p class=\"Corps\">\u00a0<\/p>\n<p class=\"Corps\">Par ailleurs, les pourparlers engag\u00e9s par Allergan au sujet du rachat de la pharmaceutique Salix seraient au point mort. En achetant Salix, Allergan ferait augmenter sa valeur \u00e0 un niveau rendant difficile son rachat par Valeant.<\/p>\n<p><br class=\"Corps\" \/><\/p>\n<p class=\"Corps\">Sources :<\/p>\n<p class=\"Corps\"><a title=\"Les actionnaires d'Allergan discuteront de l'offre d'achat hostile de Valeant\" href=\"http:\/\/agn.client.shareholder.com\/releaseDetail.cfm?ReleaseID=867860\">http:\/\/agn.client.shareholder.com\/releaseDetail.cfm?ReleaseID=867860<\/a><\/p>\n<p class=\"Corps\"><a title=\"Les actionnaires d'Allergan discuteront de l'offre d'achat hostile de Valeant\" href=\"http:\/\/agn.client.shareholder.com\/releaseDetail.cfm?ReleaseID=867446\">http:\/\/agn.client.shareholder.com\/releaseDetail.cfm?ReleaseID=867446<\/a><\/p>\n<p class=\"Corps\"><a title=\"Les actionnaires d'Allergan discuteront de l'offre d'achat hostile de Valeant\" href=\"http:\/\/eyewiretoday.com\/view.asp?20140822-allergan_talks_to_buy_salix_in_defense_move_said_to_be_dormant\">http:\/\/eyewiretoday.com\/view.asp?20140822-allergan_talks_to_buy_salix_in_defense_move_said_to_be_dormant<\/a><\/p>\n<p class=\"Corps\">\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u00a0 Allergan tiendra une r\u00e9union extraordinaire des actionnaires le 18 d\u00e9cembre 2014, afin de discuter de l'offre d'achat hostile de Valeant et Pershing Square Capital Management. \u00a0 Cette r\u00e9union \u00e9tait [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_angie_page":false,"page_builder":"","footnotes":""},"categories":[23133],"tags":[],"class_list":["post-153251","post","type-post","status-publish","format-standard","hentry","category-nouvelles"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Les actionnaires d\u0092Allergan discuteront de l\u0092offre d\u0092achat hostile de Valeant - OptikNow<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Les actionnaires d\u0092Allergan discuteront de l\u0092offre d\u0092achat hostile de Valeant - OptikNow\" \/>\n<meta property=\"og:description\" content=\"\u00a0 Allergan tiendra une r\u00e9union extraordinaire des actionnaires le 18 d\u00e9cembre 2014, afin de discuter de l&#039;offre d&#039;achat hostile de Valeant et Pershing Square Capital Management. \u00a0 Cette r\u00e9union \u00e9tait [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/v2.optiknow.ca\/fr\/2014\/08\/27\/les-actionnaires-dallergan-discuteront-de-loffre-dachat-hostile-de-valeant\/\" \/>\n<meta property=\"og:site_name\" content=\"OptikNow\" \/>\n<meta property=\"article:published_time\" content=\"2014-08-27T00:00:00+00:00\" \/>\n<meta name=\"author\" content=\"Optiknow\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Optiknow\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2014\\\/08\\\/27\\\/les-actionnaires-dallergan-discuteront-de-loffre-dachat-hostile-de-valeant\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2014\\\/08\\\/27\\\/les-actionnaires-dallergan-discuteront-de-loffre-dachat-hostile-de-valeant\\\/\"},\"author\":{\"name\":\"Optiknow\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#\\\/schema\\\/person\\\/94d0fced8e14590d08b3c02ab7a8c150\"},\"headline\":\"Les actionnaires d\u0092Allergan discuteront de l\u0092offre d\u0092achat hostile de Valeant\",\"datePublished\":\"2014-08-27T00:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2014\\\/08\\\/27\\\/les-actionnaires-dallergan-discuteront-de-loffre-dachat-hostile-de-valeant\\\/\"},\"wordCount\":313,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#organization\"},\"articleSection\":[\"Nouvelles\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2014\\\/08\\\/27\\\/les-actionnaires-dallergan-discuteront-de-loffre-dachat-hostile-de-valeant\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2014\\\/08\\\/27\\\/les-actionnaires-dallergan-discuteront-de-loffre-dachat-hostile-de-valeant\\\/\",\"url\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2014\\\/08\\\/27\\\/les-actionnaires-dallergan-discuteront-de-loffre-dachat-hostile-de-valeant\\\/\",\"name\":\"Les actionnaires d\u0092Allergan discuteront de l\u0092offre d\u0092achat hostile de Valeant - OptikNow\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#website\"},\"datePublished\":\"2014-08-27T00:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2014\\\/08\\\/27\\\/les-actionnaires-dallergan-discuteront-de-loffre-dachat-hostile-de-valeant\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2014\\\/08\\\/27\\\/les-actionnaires-dallergan-discuteront-de-loffre-dachat-hostile-de-valeant\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/2014\\\/08\\\/27\\\/les-actionnaires-dallergan-discuteront-de-loffre-dachat-hostile-de-valeant\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Les actionnaires d\u0092Allergan discuteront de l\u0092offre d\u0092achat hostile de Valeant\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/\",\"name\":\"OptikNow\",\"description\":\"Canadian Eye Care and Eyewear News for Eye Care Professionals\",\"publisher\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#organization\",\"name\":\"OptikNow\",\"url\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/v2.optiknow.ca\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/cropped-Optik-NOW_RGB.png\",\"contentUrl\":\"https:\\\/\\\/v2.optiknow.ca\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/cropped-Optik-NOW_RGB.png\",\"width\":1181,\"height\":250,\"caption\":\"OptikNow\"},\"image\":{\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/#\\\/schema\\\/person\\\/94d0fced8e14590d08b3c02ab7a8c150\",\"name\":\"Optiknow\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c3d9d9d3666433885d21222832323ad61203639f9ec9a592770d278c8df76db1?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c3d9d9d3666433885d21222832323ad61203639f9ec9a592770d278c8df76db1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c3d9d9d3666433885d21222832323ad61203639f9ec9a592770d278c8df76db1?s=96&d=mm&r=g\",\"caption\":\"Optiknow\"},\"sameAs\":[\"https:\\\/\\\/v2.optiknow.ca\"],\"url\":\"https:\\\/\\\/v2.optiknow.ca\\\/fr\\\/author\\\/optiknow\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Les actionnaires d\u0092Allergan discuteront de l\u0092offre d\u0092achat hostile de Valeant - OptikNow","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"fr_FR","og_type":"article","og_title":"Les actionnaires d\u0092Allergan discuteront de l\u0092offre d\u0092achat hostile de Valeant - OptikNow","og_description":"\u00a0 Allergan tiendra une r\u00e9union extraordinaire des actionnaires le 18 d\u00e9cembre 2014, afin de discuter de l'offre d'achat hostile de Valeant et Pershing Square Capital Management. \u00a0 Cette r\u00e9union \u00e9tait [&hellip;]","og_url":"https:\/\/v2.optiknow.ca\/fr\/2014\/08\/27\/les-actionnaires-dallergan-discuteront-de-loffre-dachat-hostile-de-valeant\/","og_site_name":"OptikNow","article_published_time":"2014-08-27T00:00:00+00:00","author":"Optiknow","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Optiknow","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/v2.optiknow.ca\/fr\/2014\/08\/27\/les-actionnaires-dallergan-discuteront-de-loffre-dachat-hostile-de-valeant\/#article","isPartOf":{"@id":"https:\/\/v2.optiknow.ca\/fr\/2014\/08\/27\/les-actionnaires-dallergan-discuteront-de-loffre-dachat-hostile-de-valeant\/"},"author":{"name":"Optiknow","@id":"https:\/\/v2.optiknow.ca\/fr\/#\/schema\/person\/94d0fced8e14590d08b3c02ab7a8c150"},"headline":"Les actionnaires d\u0092Allergan discuteront de l\u0092offre d\u0092achat hostile de Valeant","datePublished":"2014-08-27T00:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/v2.optiknow.ca\/fr\/2014\/08\/27\/les-actionnaires-dallergan-discuteront-de-loffre-dachat-hostile-de-valeant\/"},"wordCount":313,"commentCount":0,"publisher":{"@id":"https:\/\/v2.optiknow.ca\/fr\/#organization"},"articleSection":["Nouvelles"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/v2.optiknow.ca\/fr\/2014\/08\/27\/les-actionnaires-dallergan-discuteront-de-loffre-dachat-hostile-de-valeant\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/v2.optiknow.ca\/fr\/2014\/08\/27\/les-actionnaires-dallergan-discuteront-de-loffre-dachat-hostile-de-valeant\/","url":"https:\/\/v2.optiknow.ca\/fr\/2014\/08\/27\/les-actionnaires-dallergan-discuteront-de-loffre-dachat-hostile-de-valeant\/","name":"Les actionnaires d\u0092Allergan discuteront de l\u0092offre d\u0092achat hostile de Valeant - OptikNow","isPartOf":{"@id":"https:\/\/v2.optiknow.ca\/fr\/#website"},"datePublished":"2014-08-27T00:00:00+00:00","breadcrumb":{"@id":"https:\/\/v2.optiknow.ca\/fr\/2014\/08\/27\/les-actionnaires-dallergan-discuteront-de-loffre-dachat-hostile-de-valeant\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/v2.optiknow.ca\/fr\/2014\/08\/27\/les-actionnaires-dallergan-discuteront-de-loffre-dachat-hostile-de-valeant\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/v2.optiknow.ca\/fr\/2014\/08\/27\/les-actionnaires-dallergan-discuteront-de-loffre-dachat-hostile-de-valeant\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/v2.optiknow.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Les actionnaires d\u0092Allergan discuteront de l\u0092offre d\u0092achat hostile de Valeant"}]},{"@type":"WebSite","@id":"https:\/\/v2.optiknow.ca\/fr\/#website","url":"https:\/\/v2.optiknow.ca\/fr\/","name":"OptikNow","description":"Canadian Eye Care and Eyewear News for Eye Care Professionals","publisher":{"@id":"https:\/\/v2.optiknow.ca\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/v2.optiknow.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/v2.optiknow.ca\/fr\/#organization","name":"OptikNow","url":"https:\/\/v2.optiknow.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/v2.optiknow.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/v2.optiknow.ca\/wp-content\/uploads\/2025\/10\/cropped-Optik-NOW_RGB.png","contentUrl":"https:\/\/v2.optiknow.ca\/wp-content\/uploads\/2025\/10\/cropped-Optik-NOW_RGB.png","width":1181,"height":250,"caption":"OptikNow"},"image":{"@id":"https:\/\/v2.optiknow.ca\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/v2.optiknow.ca\/fr\/#\/schema\/person\/94d0fced8e14590d08b3c02ab7a8c150","name":"Optiknow","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/c3d9d9d3666433885d21222832323ad61203639f9ec9a592770d278c8df76db1?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/c3d9d9d3666433885d21222832323ad61203639f9ec9a592770d278c8df76db1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c3d9d9d3666433885d21222832323ad61203639f9ec9a592770d278c8df76db1?s=96&d=mm&r=g","caption":"Optiknow"},"sameAs":["https:\/\/v2.optiknow.ca"],"url":"https:\/\/v2.optiknow.ca\/fr\/author\/optiknow\/"}]}},"_links":{"self":[{"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/posts\/153251","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/comments?post=153251"}],"version-history":[{"count":0,"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/posts\/153251\/revisions"}],"wp:attachment":[{"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/media?parent=153251"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/categories?post=153251"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/v2.optiknow.ca\/fr\/wp-json\/wp\/v2\/tags?post=153251"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}